Protagonist Therapeutics
Quarterly Financials
| Values in thousands | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 |
|---|---|---|---|---|
Revenue | $170,638 | $4,675 | $4,167 | $254,953 |
Gross Profit | 170,638 | 4,675 | 3,275 | 254,133 |
EBITDA | 127,316 | -40,806 | -38,793 | 207,129 |
EBIT | 126,780 | -41,453 | -39,685 | 206,309 |
Net Income | 131,674 | -33,210 | -30,616 | 207,340 |
Net Change In Cash | 170,638 | 4,675 | 4,167 | 254,953 |
Free Cash Flow | -29,488 | -28,638 | 268,594 | -27,671 |
Cash | 97,249 | 131,121 | 355,643 | 172,568 |
Basic Shares | 65,077 | 61,767 | 61,305 | 63,595 |
Annual Financials
| Values in thousands | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
Revenue | $434,433 | $60,000 | $26,581 | $27,357 |
Gross Profit | 434,433 | 60,000 | 26,581 | 24,582 |
EBITDA | 252,843 | -90,340 | -128,004 | -123,070 |
EBIT | -93,652 | -131,373 | -125,845 | |
Net Income | 275,188 | -78,955 | -123,413 | -122,627 |
Net Change In Cash | 434,433 | 60,000 | 26,581 | 27,357 |
Cost of Revenue | 2,169 | 6,198 | ||
Free Cash Flow | 182,797 | -70,845 | -108,932 | -108,966 |
Cash | 97,249 | 186,727 | 125,744 | 123,665 |
Basic Shares | 65,077 | 56,763 | 49,042 | 46,322 |
Earnings Calls
| Quarter | EPS |
|---|---|
2024-12-31 | $1.98 |
2024-09-30 | -$0.54 |
2024-06-30 | -$0.50 |
2024-03-31 | $3.26 |
